AAAAAA
Results:
1-14
|
Results: 14
Authors:
du Bois, A
Luck, HJ
Pfisterer, J
Schroeder, W
Blohmer, JU
Kimmig, R
Moebus, V
Quaas, J
Citation: A. Du Bois et al., Second-line carboplatin and gemcitabine in platinum sensitive ovarian cancer - a dose-finding study by the Arbeitsgemeinschaft Gynakologische Onkologie (AGO) Ovarian Cancer Study Group, ANN ONCOL, 12(8), 2001, pp. 1115-1120
Authors:
du Bois, A
Citation: A. Du Bois, Quality assurance of surgical gynecology in Hessen - Focus on gynecologic oncology, GYNAKOLOGE, 34(2), 2001, pp. 151-155
Authors:
Gnauert, K
Lohr, A
Eitelbach, F
du Bois, A
Muller, H
Citation: K. Gnauert et al., Stereotactic methods as an alternative to conventional breast surgery for resecting mammographically suspicious lesions, GEBURTSH FR, 61(2), 2001, pp. 85-91
Authors:
du Bois, A
Citation: A. Du Bois, Anthracyclines in ovarian cancer - Past, present and future, ONKOLOGIE, 23, 2000, pp. 46-52
Authors:
du Bois, A
Luck, HJ
Bauknecht, T
Pfisterer, J
Meier, W
Citation: A. Du Bois et al., Second-line chemotherapie after platinum or platinum and paclitaxel-based chemotherapy for ovarian cancer: A systematic review, GEBURTSH FR, 60(1), 2000, pp. 41-58
Authors:
Mollenkopf, A
du Bois, A
Hummel, G
Meerpohl, HG
Citation: A. Mollenkopf et al., Management of a pregnancy complicated by idiopathic thrombozytopenic purpura and diabetes type I, Z GEBU NEON, 203(4), 1999, pp. 166-169
Authors:
du Bois, A
Schlaich, M
Luck, HJ
Mollenkopf, A
Wechsel, U
Rauchholz, M
Bauknecht, T
Meerpohl, HG
Citation: A. Du Bois et al., Evaluation of neurotoxicity induced by paclitaxel second-line chemotherapy, SUPP CARE C, 7(5), 1999, pp. 354-361
Authors:
du Bois, A
Neijt, JP
Thigpen, JT
Citation: A. Du Bois et al., First line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer - a new standard of care?, ANN ONCOL, 10, 1999, pp. 35-41
Authors:
Sessa, C
Huinink, WWT
du Bois, A
Citation: C. Sessa et al., Oxaliplatin in ovarian cancer, ANN ONCOL, 10, 1999, pp. 55-57
Authors:
Berek, JS
Bertelsen, K
du Bois, A
Brady, MF
Carmichael, J
Eisenhauer, EA
Gore, M
Grenman, S
Hamilton, TC
Hansen, SW
Harper, PG
Horvath, G
Kaye, SB
Luck, HJ
Lund, B
McGuire, WP
Neijt, JP
Ozols, RF
Parmar, MKB
Piccart-Gebhart, MJ
van Rijswijk, R
Rosenberg, P
Rustin, GJS
Sessa, C
Thigpen, JT
Trope, C
Tuxen, MK
Vergote, I
Vermorken, JB
Willemse, PHB
Citation: Js. Berek et al., Advanced epithelial ovarian cancer: 1998 consensus statements, ANN ONCOL, 10, 1999, pp. 87-92
Authors:
du Bois, A
Luck, HJ
Bauknecht, T
Meier, W
Richter, B
Kuhn, W
Quaas, J
Pfisterer, J
Citation: A. Du Bois et al., First-line chemotherapy with epirubicin, paclitaxel, and carboplatin for advanced ovarian cancer: A phase I/II study of the Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer Study Group, J CL ONCOL, 17(1), 1999, pp. 46-51
Authors:
du Bois, A
Luck, HJ
Bauknecht, T
Citation: A. Du Bois et al., First-line chemotherapy in advanced ovarian cancer: State of the art and future aspects, ONKOLOGIE, 22(4), 1999, pp. 269-280
Authors:
Neijt, JP
du Bois, A
Citation: Jp. Neijt et A. Du Bois, Paclitaxel/carboplatin for the initial treatment of advanced ovarian cancer, SEMIN ONCOL, 26(1), 1999, pp. 78-83
Authors:
du Bois, A
Citation: A. Du Bois, Support measures in therapy for gynecological malignant tumors. Side effects of chemotherapy and their treatment, GYNAKOLOGE, 32(10), 1999, pp. 805-815
Risultati:
1-14
|